Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection
-
- Robert E. Lanford
- Department of Virology and Immunology and Southwest National Primate Research Center, Southwest Foundation for Biomedical Research, San Antonio, TX 78227, USA.
-
- Elisabeth S. Hildebrandt-Eriksen
- Santaris Pharma, Kogle Allé 6, DK-2970 Hørsholm, Denmark.
-
- Andreas Petri
- Santaris Pharma, Kogle Allé 6, DK-2970 Hørsholm, Denmark.
-
- Robert Persson
- Santaris Pharma, Kogle Allé 6, DK-2970 Hørsholm, Denmark.
-
- Morten Lindow
- Santaris Pharma, Kogle Allé 6, DK-2970 Hørsholm, Denmark.
-
- Martin E. Munk
- Santaris Pharma, Kogle Allé 6, DK-2970 Hørsholm, Denmark.
-
- Sakari Kauppinen
- Santaris Pharma, Kogle Allé 6, DK-2970 Hørsholm, Denmark.
-
- Henrik Ørum
- Santaris Pharma, Kogle Allé 6, DK-2970 Hørsholm, Denmark.
説明
<jats:title>Anti-MicroRNA Antiviral</jats:title> <jats:p> MicroRNAs (miRNAs) are small noncoding RNAs found in eukaryotes and viruses. They are critical regulators of a wide range of cellular processes. The highly conserved miRNA miR-122 is required for infection by hepatitis C virus (HCV), a leading cause of liver disease in humans. Present HCV treatment regimes can have serious side effects and are effective in only 50% of cases. In order to try to tackle HCV infection, <jats:bold> Lanford <jats:italic>et al.</jats:italic> </jats:bold> (p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" page="198" related-article-type="in-this-issue" vol="327" xlink:href="10.1126/science.1178178">198</jats:related-article> , published online 3 December) targeted miR-122 using a complementary locked nucleic acid (LNA) oligonucleotide. Treatment of chimpanzees infected by HCV with the LNA antagonist resulted in a long-term reduction of disease symptoms without the concomitant appearance of resistant strains of the virus. </jats:p>
収録刊行物
-
- Science
-
Science 327 (5962), 198-201, 2010-01-08
American Association for the Advancement of Science (AAAS)